Dataset from A Multicenter, Randomized, Double-Blind, Parallel-Group, Phase 3 Study to Evaluate the Efficacy and Safety of Oral TAK-385 40 mg Compared With Leuprorelin in the Treatment of Uterine Fibroids

The purpose of this study is to evaluate the efficacy of Relugolix (TAK-385) 40 mg
administered orally once daily for 12 weeks, compared with leuprorelin injection (once every
4 weeks, 1.88 mg or 3.75 mg subcutaneously [SC]/time) in patients with uterine fibroids.

本研究旨在评估每日一次口服40mg瑞卢戈利（Relugolix，TAK-385）连续给药12周的临床疗效，并与每4周一次皮下注射（SC）1.88mg或3.75mg亮丙瑞林注射液的给药方案进行对比，研究对象为子宫肌瘤患者。